Publications by authors named "Christopher N Selverian"
Article Synopsis
- Monkeypox virus (MPXV) is causing a global outbreak, raising questions about different antibody responses from vaccination versus actual infection.
- A study found that convalescent individuals (those who recovered from MPXV) had higher neutralizing antibodies against the virus compared to vaccinated and non-infected people one month after exposure.
- Both groups experienced a significant decrease in antibody levels after eight months, indicating a need for improved vaccine strategies to ensure longer-lasting immunity and reduce breakthrough infections.
Article Synopsis
- Understanding how our body fights off new viruses, like Ebola, helps us prepare for outbreaks.
- Scientists studied special immune cells called B cells to see how they make antibodies against the Ebola virus.
- They found 73 types of antibodies that can fight off the virus, which can help create better vaccines and treatments in the future.
The protective human antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) focuses on the spike (S) protein, which decorates the virion surface and mediates cell binding and entry. Most SARS-CoV-2 protective antibodies target the receptor-binding domain or a single dominant epitope ("supersite") on the N-terminal domain (NTD). Using the single B cell technology called linking B cell receptor to antigen specificity through sequencing (LIBRA-Seq), we isolated a large panel of NTD-reactive and SARS-CoV-2-neutralizing antibodies from an individual who had recovered from COVID-19.
View Article and Find Full Text PDFArticle Synopsis
- Researchers are investigating therapeutic monoclonal antibodies (mAbs) targeting different vulnerable sites on the SARS-CoV-2 spike protein to prevent the virus from escaping treatment and to enhance protection against variants.
- They discovered several effective neutralizing antibodies that can be used in combination, showing strong protection in a mouse model of infection.
- One specific RBD antibody, WRAIR-2125, was particularly effective against all major variants and, when used with other mAbs, helped prevent the virus from evading the immune response.